ClinicalTrials.gg
RecruitingNCT07155005SCOREUpdated Nov 2, 2026

Stone Clearance With Aspiration vs Other Technologies: a Real-world Evidence Study

An observational study in Urolithiasis, Stones, Kidney and Renal Stones, sponsored by Calyxo, Inc.. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Primary conditionKidney CalculiRegistry: UrolithiasisReclassifiedWhy we changed it
Registry
Urolithiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Calculi
Why
  1. The study's listed conditions name Kidney Calculi, a narrower term within Urolithiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Calyxo, Inc. · Observational

Updated Nov 2, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the effectiveness and safety of Steerable Ureteroscopic Renal Evacuation (SURE) with the CVAC System versus other commonly used renal-stone interventions.

Read the detailed description

Up to 25 sites, and up to 250 subjects will be prospectively enrolled for phase 1: CVAC and FANS cohorts.

02

Conditions studied

  • Urolithiasis
  • Stones, Kidney
  • Renal Stones
  • Kidney Stones

Browse trials for

Keywords

  • ureteroscopy
  • CVAC
  • SURE
  • URS
03

In context

Kidney Calculi Reclassified

509 studies on the registry are indexed under Kidney Calculi; 146 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 160 across 96 observational studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

Calyxo, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Compared within Kidney Calculi, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urolithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Candidate for ureteroscopy with laser lithotripsy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Candidate for ureteroscopy with laser lithotripsy or PCNL for the treatment of renal stones
  • Be willing and able to return for and respond to all study-related follow up procedures
  • Have been informed of the nature of the study and has provided using the IRB approved informed consent (ICF)

Exclusion criteria

Exclusion Criteria:

  • Untreated urinary tract infection at the time of the index procedure
  • Visual evidence of infection at the time of the index procedure
  • History of sepsis
  • Significant comorbidities
  • Bladder, ureteral or kidney abnormalities
  • Pregnant individuals
  • Unable to meet the treatment and follow up protocol requirements
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • PERCUTANEOUS NEPHROLITHOTOMY (PCNL)

    This is a surgical procedure under general anesthesia, where a rigid probe is placed through the flank, creating a percutaneous tract into the renal collecting system under fluoroscopy. Via nephoscopy, stones are fragmented, pulverized, and extracted.

    Procedure: PERCUTANEOUS NEPHROLITHOTOMY (PCNL)

  • DIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS)

    DISS is a system that integrates controlled suction into the working channel of a standard flexible ureteroscope during ureteroscopic lithotripsy. A suction adapter is attached externally to the ureteroscope's working port, which connects to a standard hospital suction source.

    Device: DIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS)

  • URETEROSCOPY (URS) WITHOUT SUCTION

    URS allows the surgeon to visualize the stone by inserting the ureteroscope into the ureter, most often a flexible scope that allows them to accommodate to the shape of the ureter and renal collecting system. A laser fiber is advanced through the working channel of the ureteroscope to perform stone fragmentation (dusting or breaking up the calculi). Once the stones are dusted or fragmented, the pieces can be removed by active extraction of individual stone fragments using a retrieval basket or using the concept of stone dusting where the fragments are small enough to be passed after the procedure.

    Procedure: URETEROSCOPY (URS) WITHOUT SUCTION

  • FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS)

    FANS is designed to incorporate suction to facilitate stone fragment removal through its lumen and is used with a separate ureteroscope. FANS is fitted with a Y connector with a pressure control vent and connects to a standard vacuum device. A separate ureteroscope provides direct visualization and irrigation and a separate specimen collector captures stone debris.

    Device: FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS)

  • CVAC® SYSTEM

    The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).

    Device: CVAC® SYSTEM

Interventions

  • DeviceCVAC® SYSTEM

    The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).

    Also known as: SURE, CVAC

  • DeviceFLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS)

    Group/Cohort Description: FANS is designed to incorporate suction to facilitate stone fragment removal through its lumen and is used with a separate ureteroscope. FANS is fitted with a Y connector with a pressure control vent and connects to a standard vacuum device. A separate ureteroscope provides direct visualization and irrigation and a separate specimen collector captures stone debris.

    Also known as: FANS

  • DeviceDIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS)

    DISS is a system that integrates controlled suction into the working channel of a standard flexible ureteroscope during ureteroscopic lithotripsy. A suction adapter is attached externally to the ureteroscope's working port, which connects to a standard hospital suction source.

    Also known as: DISS

  • ProcedureURETEROSCOPY (URS) WITHOUT SUCTION

    URS allows the surgeon to visualize the stone by inserting the ureteroscope into the ureter, most often a flexible scope that allows them to accommodate to the shape of the ureter and renal collecting system. A laser fiber is advanced through the working channel of the ureteroscope to perform stone fragmentation (dusting or breaking up the calculi). Once the stones are dusted or fragmented, the pieces can be removed by active extraction of individual stone fragments using a retrieval basket or using the concept of stone dusting where the fragments are small enough to be passed after the procedure.

    Also known as: URS, Dusting, Basketing

  • ProcedurePERCUTANEOUS NEPHROLITHOTOMY (PCNL)

    This is a surgical procedure under general anesthesia, where a rigid probe is placed through the flank, creating a percutaneous tract into the renal collecting system under fluoroscopy. Via nephoscopy, stones are fragmented, pulverized, and extracted.

    Also known as: PCNL

06

What researchers measure

Primary outcomes

  1. Residual Stone Volume (RSV)

    Time frame: 30-Day

07

Study locations

10 of 10 sites recruiting
08

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
10 sites added — first site in United States
Show 10 added (10 United States)
  • University of Miami · Miami, United States
  • Wichita Urology Group · Wichita, United States
  • University of Buffalo · Cheektowaga, United States
  • Integrated Medical Professionals (IMP) · New York, United States
  • Northwell Health · New York, United States
  • Urology Specialists of the Carolinas (USOC) · Charlotte, United States
  • The Urology Group · Cincinnati, United States
  • Urology Specialists of South Dakota · Sioux Falls, United States
  • Urology Partners of North Texas · Arlington, United States
  • UT Southwestern Medical Center · Dallas, United States
Nov 2, 2026
Start date
Mar 16, 2026→Oct 12, 2026 (actual)
Nov 2, 2026
Primary completion
Apr 2028→Dec 2028
Nov 2, 2026
Study completion
Apr 2029→Dec 2029
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    10 sites added — first site in United States
    Show 10 added (10 United States)
    • University of Miami · Miami, United States
    • Wichita Urology Group · Wichita, United States
    • University of Buffalo · Cheektowaga, United States
    • Integrated Medical Professionals (IMP) · New York, United States
    • Northwell Health · New York, United States
    • Urology Specialists of the Carolinas (USOC) · Charlotte, United States
    • The Urology Group · Cincinnati, United States
    • Urology Specialists of South Dakota · Sioux Falls, United States
    • Urology Partners of North Texas · Arlington, United States
    • UT Southwestern Medical Center · Dallas, United States
    Start date Mar 16, 2026→Oct 12, 2026 (now actual)
    Primary completion Apr 2028→Dec 2028
    Study completion Apr 2029→Dec 2029
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07155005
Lead sponsor
Calyxo, Inc.
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Oct 12, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion